Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
September 2022
-
Media ReleaseNovartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management eventTransformation to pure-play Innovative Medicines company nears completion Focusing strategy on five core Therapeutic Areas, key technology platforms, and the USAdvancing eight in-market brands with…
-
Media ReleaseNovartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patentAd hoc announcement pursuant to Art. 53 LR Basel, 21 September, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its…
-
Media ReleaseSandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trialROSALIA study met primary endpoints, confirming proposed biosimilar denosumab matches reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in…
-
Media ReleaseNovartis statement regarding competition authority investigation into assertion of a patentCompany confident to clarify legitimacy of its position and fully cooperating with authoritiesBasel, September 15, 2022 — Novartis today confirms that it has been contacted by the Swiss Competition…
-
Media ReleaseNovartis invests in early technical development capabilities for next-generation biotherapeuticsMulti-year investment of USD 300m will create integrated scientific environment to deliver on increasing growth and diversity of biotherapeutics portfolio Enhanced capacity and processes expected to…
-
Featured NewsNovartis Hematology: Working to help ensure patients are getting the access they need
-
Media ReleaseNovartis announces tislelizumab demonstrated efficacy and tolerability in first-line advanced liver cancer in Phase III trialRATIONALE 301 trial met its objective at final analysis, demonstrating non-inferior overall survival (OS) for tislelizumab (median OS: 15.9 months) versus sorafenib (median OS: 14.1 months) in…
-
Media ReleaseNovartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trialsResults from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and…
-
Media ReleaseNovartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancerNew large pooled exploratory analysis from MONALEESA-2, -3 and -7 reinforces unparalleled overall survival (OS) benefit of Kisqali plus ET compared to ET alone, in HR+/HER2- aBC patients with…
-
Media ReleaseNovartis highlights depth of immunology pipeline with novel data at key upcoming international congressesPivotal results for efficacy and safety of Cosentyx® (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of…
-
Media ReleaseNovartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., steps down from the Executive Committee of NovartisAfter seven years as President of NIBR and a member of the ECN, Dr. Bradner will pursue a next chapter of scientific contribution and leadership outside of NovartisBuilding on NIBR foundation, Dr.…